# Observation of the Immune Response After COVID-19 Additional Vaccine Doses in Chronic Patients in Hemodialysis Therapy

> **NCT05142501** · — · TERMINATED · sponsor: **Fresenius Medical Care Deutschland GmbH** · enrollment: 23 (actual)

## Conditions studied

- Chronic Kidney Diseases
- COVID-19
- Hemodialysis

## Interventions

- **OTHER:** Blood samples

## Key facts

- **NCT ID:** NCT05142501
- **Lead sponsor:** Fresenius Medical Care Deutschland GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-25
- **Primary completion:** 2022-09-02
- **Final completion:** 2022-09-02
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Low recruitment
- **Last updated:** 2022-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05142501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05142501, "Observation of the Immune Response After COVID-19 Additional Vaccine Doses in Chronic Patients in Hemodialysis Therapy". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05142501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*